Javier
Pérez Gisbert
Publicacións nas que colabora con Javier Pérez Gisbert (9)
2022
-
Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)
Journal of Clinical Medicine
-
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 128-140
-
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 118-127
2021
-
Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study
Journal of Clinical Medicine, Vol. 10, Núm. 13
2019
-
Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
Therapeutic Advances in Gastroenterology, Vol. 12
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
2013
-
New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients
Pharmacogenomics, Vol. 14, Núm. 6, pp. 631-640
2012
-
Tu1909 An Exome-Wide Genotyping Analysis for the Identification of Candidate Genes Associated With the Response to the Thiopurine Therapy in Inflammatory Bowel Disease Patients
Gastroenterology, Vol. 142, Núm. 5, pp. S-875
2011
-
New Genetic Associations Detected in an Exome-Wide Association Study for Toxicity Related to Thiopurine Treatments in Inflammatory Bowel Disease
Gastroenterology, Vol. 140, Núm. 5, pp. S-271